ORX489

ORX489 is an investigational, orally administered small molecule agonist of orexin receptor type 2 (OX2R), developed by Centessa Pharmaceuticals. It is part of a pipeline of highly potent and selective OX2R agonists designed to address neuropsychiatric disorders. Orexin receptor 2 agonists are being explored for their potential to treat excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue, and other symptoms associated with neurological, neurodegenerative, and neuropsychiatric conditions. The mechanism involves activation of the orexin system in the brain to promote wakefulness and regulate the sleep-wake cycle[1][2][9].